Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
B7 family member zB7H6 and related compositions and methods
US8969518B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8969518-B2 |
| Application number | US-94325610-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 10, 2010 |
| Priority date | Oct 4, 2007 |
| Publication date | Mar 3, 2015 |
| Grant date | Mar 3, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated, soluble fusion protein comprising a polypeptide segment that has at least 90% sequence identity with the amino acid sequence set forth in residues 25-266 of SEQ ID NO:2, wherein said polypeptide is capable of specifically binding to human natural killer cell receptor NKp30, and wherein said fusion protein further comprises a vasodilator-stimulated phosphoprotein (VASP) domain. 2. The fusion protein of claim 1 , wherein the po…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8969518B2 cover?
- Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates co…
- Who is the assignee on this patent?
- Brandt Cameron S, Kennedy Jacob J, Xu Wenfeng, and 5 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2827. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).